<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Braz J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Int Braz J Urol</journal-id><journal-id journal-id-type="publisher-id">ibju</journal-id><journal-title-group><journal-title>International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology</journal-title></journal-title-group><issn pub-type="ppub">1677-5538</issn><issn pub-type="epub">1677-6119</issn><publisher><publisher-name>Sociedade Brasileira de Urologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27564283</article-id><article-id pub-id-type="pmc">5006768</article-id><article-id pub-id-type="publisher-id">S1677-5538.IBJU.2015.0570</article-id><article-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2015.0570</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Junping</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Minjie</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shucheng</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Yajun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><aff id="aff1"><label>1</label>Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</aff><aff id="aff2"><label>2</label>Department of Urology, Jingmen No.1 People's Hospital, Jingmen, Hubei, China</aff><aff id="aff3"><label>3</label>Department of Urology, Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China</aff></contrib-group><author-notes><corresp id="c1"><bold>Correspondence address:</bold> Yajun Xiao, MD, Department of Urology, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, 1277 Jiefang Road, Wuhan, Hubei 430022, China, Fax: <fax>+86 27 8572-6970</fax>, E-mail address: <email>xiaoyjuh@163.com</email></corresp><fn fn-type="COI-statement"><p>
<bold>CONFLICT OF INTEREST</bold>
</p><p>None declared.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2016</year></pub-date><volume>42</volume><issue>4</issue><fpage>727</fpage><lpage>733</lpage><history><date date-type="received"><day>05</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>12</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>ABSTRACT</title><sec><title>Objective:</title><p>To assess the impact of Doxazosin Oral Intake Therapy on urinary symptoms and pain in patients with indwelling ureteral stents</p></sec><sec><title>Patients and Methods:</title><p>A total of 239 patients with ureteral stone-related hydronephrosis who underwent a double-J stent insertion after ureteroscopic lithotripsy were enrolled. Patients were randomized to receive doxazosin cotrolled release 4 mg once daily for 4 weeks or matching placebo. Patients completed the brief-form Chinese version Ureteric Stent Symptom Questionnaire (USSQ) and quality of life (QoL) score 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal. The analgesic use was also recorded during the stenting period.</p></sec><sec><title>Results:</title><p>Patients in Doxazosin Oral Intake Therapy group, in the first 2 weeks and second 2 weeks with the stent in situ, expressed significant lower daytime frequency (p=0.028 and p=0.038), nocturia (p=0.021 and p=0.008) and urgency (p=0.012 and p=0.014), respectively. Similarly, flank pain score, QoL score and analgesic use were also significant less in the stenting period. There was no significant difference in scores of urinary symptoms, pain and QoL during the post-stent period between two cohorts.</p></sec><sec><title>Conclusions:</title><p>Doxazosin Oral Intake Therapy reduced stent-related urinary symptoms, pain and the negative impact on QoL.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>Quality of Life</kwd><kwd>Doxazosin</kwd><kwd>Lower Urinary Tract Symptoms</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="19"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>More than four decades have passed since the first description of an indwelling ureteral stent by Zimskind et al. (<xref rid="B1" ref-type="bibr">1</xref>). Placement of ureteral stent after ureteroscopic procedure remains common practice. However, morbidity associated with the stent has been well documented. In particular, general health and work performance were impacted by bothersome urinary symptoms in 80% cases and pain in 78% (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>).</p><p>Several studies have demonstrated &#x003b1;-blockers, such as alfuzosin and tamsulosin, improving stent-related symptoms (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B7" ref-type="bibr">7</xref>). However, the results showed some fluctuations (<xref rid="B7" ref-type="bibr">7</xref>). Doxazosin Oral Intake Therapy has been shown to offer enhanced delivery rate, pharmacokinetic profile and compliance in patients with benign prostate hyperplasia (BPH) (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). In addition, it might interact with &#x003b1;1-adrenergic receptor subtype located in central nervous system (CNS) for producing maximum benefit (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Herein, we firstly performed a double-blind, randomized, placebo controlled study to assess the impact of Doxazosin Oral Intake Therapy on stent-related urinary symptoms and pain.</p></sec><sec sec-type="methods"><title>PATIENTS AND METHODS</title><p>This study was conducted with the institutional review approval. From June 2013 to February 2015, patients with unilateral hydronephrosis associated with ureteral stone to be treated with ureteroscopic lithotripsy and an indwelling ureteral stent insertion for 4 weeks were assumed for enrollment in the study. After documentation of informed consent, patients were randomized (using a Table with random number) to 1 of 2 treatment groups: doxazosin controlled release 4mg daily for 4 weeks (Carduran XL&#x000ae;, Pfizer Pharmaceuticals, Vega Baja) or matching placebo once daily for 4 weeks. Both investigators and patients were blinded to the randomization scheme and medication. Patients were asked to take 1 tablet on postoperative day 1.</p><p>Patients with bilateral stones, pregnancy or probable pregnancy, nursing, symptoms of BPH, urinary tract infection, chronic pain history, &#x003b1;-blocker or anticholinergic use in previous 3 months, hypotension or orthostatic hypotension history (resting blood pressure less than 100/70mmHg), age less than 18 years and other contraindications indicated in package insert were excluded.</p><p>Ureteroscopic lithotripsy was initially conducted with a Wolf 8F/9.8F semirigid ureteroscope in all patients. Stones were fragmented to less than 2mm using 0.8J 10Hz Holmium: YAG laser and a 200&#x003bc;m fiber. When flexible ureteroscope was required, a 12/14F dual lumen ureteral access sheath (Flexor&#x000ae; DL, Cook Urologic, Spencer, IN) was introduced over a working guidewire. A 6Fr indwelling double-J stent (Inlay optima&#x000ae;, Bard Medical, Convington, GA) was placed under fluoroscopic and cystoscopic control. Appropriate length was evaluated according to patient height. Stent position was examined radiographically.</p><p>The primary endpoints were the assessment of urinary symptoms and pain. The secondary endpoints included QoL, analgesics use and treatment emergent adverse event (TEAE). To assess urinary symptoms and pain associated with ureteral stent, patients were asked to complete the brief-form Chinese version USSQ 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal (<xref rid="B11" ref-type="bibr">11</xref>). The outcomes obtained at 4 weeks after stent withdrawal were proposed to be the baseline data without the impact of ureteral stone and related hydronephrosis (<xref rid="B6" ref-type="bibr">6</xref>). Patients received a prescription for diclofenac sodium 50mg&#x000d7;10 suppositories. A log sheet of analgesic use was kept during the stenting period.</p><p>The brief-form Chinese version USSQ, a simplified condition-specific questionnaire for evaluation of stent-related urinary symptoms and pain in the past 2 weeks, was adopted from the validated International Prostate Symptom Scale (IPSS) (<xref rid="B11" ref-type="bibr">11</xref>). The procedure of back translation was performed to verify the utility for covering the urinary symptoms section and pain section of the original USSQ initiated by Joshi et al. (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Accordingly, QoL of IPSS was also assessed in our study (<xref rid="B13" ref-type="bibr">13</xref>). The individual index has a score ranging from 0 to 5 (or QoL score of 6), with high scores corresponding to worse outcomes.</p><p>A sample size of 218 patients was calculated based on a power of 80% and a significant level of 0.05 to detect 30% difference in flank pain scores and 26% difference in frequency scores in the first 2 weeks with the stent in situ (<xref rid="B11" ref-type="bibr">11</xref>). Descriptive statistics included mean&#x000b1;SD for continuous variables, number and percentage for categorical variables. Student t test, chi-square test and non-parameter Wilcoxon test were used, as appropriate. Analyses were performed on full per-protocol set population as it was determined more appropriate to exclude those who failed to complete the study. A p value &#x0003c;0.05 was considered significant. Statistic analyses were conducted using computer software (Package for Social Science 19.0, SPSS Inc., Chicago, IL).</p></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 239 patients were enrolled, 231 of whom were randomly assigned to either Doxazosin Oral Intake Therapy or placebo group. The total number of patients that completed the study at 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal were 219, 212 and 201, respectively. The main reasons for discontinuation were loss during follow-up, protocol deviation, withdrawal of consent and TEAE.</p><p>Patient demographics are listed in <xref ref-type="table" rid="t1">Table-1</xref>. Average patient age was 45.7 years (range 26 to 66), and the overall distribution of female and male was 29% and 71%, respectively. There was no significant difference in age, gender, stone size, stone location, height and length of stent between 2 cohorts.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient characteristics.</title></caption><table frame="hsides" rules="groups"><colgroup width="24%" span="1"><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#E7E7E8"><th align="left" colspan="2" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Doxazosin</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" colspan="2" rowspan="1">No. of Patients</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" colspan="2" rowspan="1">Age (y), Mean &#x000b1; SD (Range)</td><td align="center" rowspan="1" colspan="1">44.7 &#x000b1; 9.4 (26-64)</td><td align="center" rowspan="1" colspan="1">46.6 &#x000b1;8.2 (30-66)</td><td align="center" rowspan="1" colspan="1">0.12<xref ref-type="fn" rid="TFN2">*</xref>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Gender, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.46<xref ref-type="fn" rid="TFN3">&#x02020;</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">35(31)</td><td align="center" rowspan="1" colspan="1">28 (26)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">77(69)</td><td align="center" rowspan="1" colspan="1">79(74)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Laterality, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.13<xref ref-type="fn" rid="TFN3">&#x02020;</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Left</td><td align="center" rowspan="1" colspan="1">53(47)</td><td align="center" rowspan="1" colspan="1">39(36)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Right</td><td align="center" rowspan="1" colspan="1">59(53)</td><td align="center" rowspan="1" colspan="1">68(64)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Stone size (mm). Mean &#x000b1;SD</td><td align="center" rowspan="1" colspan="1">8.2 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">7.8 &#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">0.27<xref ref-type="fn" rid="TFN2">*</xref>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Stone location, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.56<xref ref-type="fn" rid="TFN3">&#x02020;</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Upper</td><td align="center" rowspan="1" colspan="1">19(17)</td><td align="center" rowspan="1" colspan="1">13 (12)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Middle</td><td align="center" rowspan="1" colspan="1">20(18)</td><td align="center" rowspan="1" colspan="1">18(17)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="center" rowspan="1" colspan="1">73(65)</td><td align="center" rowspan="1" colspan="1">76(71)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Height (cm). Meant &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">164.4 &#x000b1; 6.5</td><td align="center" rowspan="1" colspan="1">163.6 &#x000b1; 6.2</td><td align="center" rowspan="1" colspan="1">0.31<xref ref-type="fn" rid="TFN2">*</xref>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Length of stent, n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.35<xref ref-type="fn" rid="TFN3">&#x02020;</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24 cm</td><td align="center" rowspan="1" colspan="1">50(45)</td><td align="center" rowspan="1" colspan="1">55(51)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26 cm</td><td align="center" rowspan="1" colspan="1">62(55)</td><td align="center" rowspan="1" colspan="1">52 (49)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>NA not applicants</p></fn><fn id="TFN2"><label>*</label><p>Student t test</p></fn><fn id="TFN3"><label>&#x02020;</label><p>Chi-square test</p></fn></table-wrap-foot></table-wrap><p>The overall study results are presented in <xref ref-type="table" rid="t2">Table-2</xref>. Patients receiving Doxazosin Oral Intake Therapy expressed significant lower daytime frequency (p=0.028 and p=0.038, respectively), nocturia (p=0.021 and p=0.008, respectively) and urgency (p=0.012 and p=0.014, respectively) in the first 2 weeks and second two weeks with the stent in situ when compared to the placebo group. Similarly, there were marked decreases in flank pain and abdominal pain that were associated with Doxazosin Oral Intake Therapy. Mean analgesics use and QoL scores were also significant lower in Doxazosin Oral Intake Therapy group during the stenting period.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Overall study results.</title></caption><table frame="hsides" rules="groups"><colgroup width="24%" span="1"><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#E7E7E8"><th align="left" colspan="2" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Doxazosin</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" colspan="5" rowspan="1">
<bold>Daytime Frequency</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">2.18 &#x000b1;1.80</td><td align="center" rowspan="1" colspan="1">2.68 &#x000b1; 2.00</td><td align="center" rowspan="1" colspan="1">0.028</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">1.98 &#x000b1;1.64</td><td align="center" rowspan="1" colspan="1">2.48 &#x000b1;1.81</td><td align="center" rowspan="1" colspan="1">0.038</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">1.08 &#x000b1;1.24</td><td align="center" rowspan="1" colspan="1">1.33 &#x000b1;1.41</td><td align="center" rowspan="1" colspan="1">0.266</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Nocturia</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.35 &#x000b1;1.46</td><td align="center" rowspan="1" colspan="1">1.88 &#x000b1;1.74</td><td align="center" rowspan="1" colspan="1">0.021</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">1.05 &#x000b1;1.18</td><td align="center" rowspan="1" colspan="1">1.66 &#x000b1;1.62</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.42 &#x000b1; 0.83</td><td align="center" rowspan="1" colspan="1">0.49 &#x000b1; 0.90</td><td align="center" rowspan="1" colspan="1">0.749</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Urgency</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.33 &#x000b1;1.67</td><td align="center" rowspan="1" colspan="1">1.93 &#x000b1;1.74</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">1.13 &#x000b1;1.33</td><td align="center" rowspan="1" colspan="1">1.67 &#x000b1;1.57</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.68 &#x000b1;1.26</td><td align="center" rowspan="1" colspan="1">0.77 &#x000b1; 0.97</td><td align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Urge incontinence</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">0.09 &#x000b1; 0.32</td><td align="center" rowspan="1" colspan="1">0.14 &#x000b1;0.46</td><td align="center" rowspan="1" colspan="1">0.676</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.06 &#x000b1; 0.23</td><td align="center" rowspan="1" colspan="1">0.08 &#x000b1; 0.27</td><td align="center" rowspan="1" colspan="1">0.510</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.02 &#x000b1;0.14</td><td align="center" rowspan="1" colspan="1">0.232</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Hematuria</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.20 &#x000b1;1.62</td><td align="center" rowspan="1" colspan="1">1.26 &#x000b1;1.52</td><td align="center" rowspan="1" colspan="1">0.644</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.86 &#x000b1;1.28</td><td align="center" rowspan="1" colspan="1">1.05 &#x000b1;1.25</td><td align="center" rowspan="1" colspan="1">0.141</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.27 &#x000b1; 0.56</td><td align="center" rowspan="1" colspan="1">0.16 &#x000b1;0.43</td><td align="center" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Flank pain</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.13 &#x000b1;1.46</td><td align="center" rowspan="1" colspan="1">1.83 &#x000b1;1.92</td><td align="center" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.93 &#x000b1;1.18</td><td align="center" rowspan="1" colspan="1">1.45 &#x000b1;1.54</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.18 &#x000b1;0.55</td><td align="center" rowspan="1" colspan="1">0.31 &#x000b1; 0.67</td><td align="center" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Abdominal pain</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.03 &#x000b1;1.30</td><td align="center" rowspan="1" colspan="1">1.60 &#x000b1;1.74</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.80 &#x000b1;1.08</td><td align="center" rowspan="1" colspan="1">1.50 &#x000b1;1.55</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.13 &#x000b1;0.39</td><td align="center" rowspan="1" colspan="1">0.29 &#x000b1; 0.66</td><td align="center" rowspan="1" colspan="1">0.074</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Urethral pain</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">1.07 &#x000b1;1.33</td><td align="center" rowspan="1" colspan="1">1.45 &#x000b1;1.82</td><td align="center" rowspan="1" colspan="1">0.236</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.72 &#x000b1;1.02</td><td align="center" rowspan="1" colspan="1">1.27 &#x000b1;1.56</td><td align="center" rowspan="1" colspan="1">0.021</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">0.18 &#x000b1;0.54</td><td align="center" rowspan="1" colspan="1">0.21 &#x000b1; 0.52</td><td align="center" rowspan="1" colspan="1">0.610</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>QoL</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">2.79 &#x000b1;1.05</td><td align="center" rowspan="1" colspan="1">3.27 &#x000b1;1.32</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">2.69 &#x000b1; 0.97</td><td align="center" rowspan="1" colspan="1">3.00 &#x000b1;1.07</td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Post-stent</td><td align="center" rowspan="1" colspan="1">1.44 &#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">1.57 &#x000b1;0.69</td><td align="center" rowspan="1" colspan="1">0.273</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Analgesics use</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">First 2 weeks</td><td align="center" rowspan="1" colspan="1">0.30 &#x000b1; 0.79</td><td align="center" rowspan="1" colspan="1">0.74 &#x000b1;1.29</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Second 2 weeks</td><td align="center" rowspan="1" colspan="1">0.20 &#x000b1; 0.62</td><td align="center" rowspan="1" colspan="1">0.53 &#x000b1;1.02</td><td align="center" rowspan="1" colspan="1">0.006</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>Values in both treatment groups are presented by mean &#x000b1; standard deviation</p></fn><fn id="TFN5"><p>Mann-Whitney U test was used for all statistical analyses.</p></fn></table-wrap-foot></table-wrap><p>There was no significant difference in scores of urinary symptoms, pain and QoL in the post-stent period between two groups, which were considered as the baseline characteristics.</p><p>Four patients in Doxazosin Oral Intake Therapy experienced mild TEAE (dizziness in 3 and orthostatic hypotension in 1), and two of them discontinued medication, and symptoms disappeared after discontinuation.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>To our knowledge, this is the first double-blind, placebo controlled study to demonstrate the effectiveness of Doxazosin Oral Intake Therapy in reducing ureteral stent-related discomforts. A range of patient urinary symptoms and pain were improved, including frequency, nocturia, urgency, flank pain, abdominal pain. Patients QoL seemed to be better preserved also. The sample size per group in the study was the biggest in relevant literature. The same type of stent and indication were controlled to minimize related biases.</p><p>Although there have been lots of advances in ureteral stent composition and constructions design directed at improving biocompatibility and patient relevant symptoms, the ideal biomaterial for stent has yet to be discovered (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). In contrary to stent engineering research, several studies suggested that &#x003b1;-blockers would be effective (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Deliveliotis et al. firstly reported that alfuzosin improved a subset of urinary symptoms and pain in patients with an indwelling double-J stent using USSQ 4 weeks after stent insertion (<xref rid="B4" ref-type="bibr">4</xref>). Then another two studies elucidating the efficacy of alfuzosin and tamsulosin on stent symptoms were performed by Buddingfield et al. and Damino et al., respectively (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Meta-analyses also showed that &#x003b1;-blockers are associated with improvements in stent symptoms (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>).</p><p>Recently, Dellis et al. reported that tamsulosin and alfuzosin reduced stent-related symptoms in patients with hydronephrosis associated ureteral stone who underwent stent placement, routinely for 4 weeks, after extracorporeal shock wave lithotripsy (SWL, n=106) or ureteroscopic lithotripsy (n=44) using the USSQ as originally intended by Joshi et al. 1 week and 4 weeks after stent placement and 4 weeks after stent removal (<xref rid="B7" ref-type="bibr">7</xref>). In our study, we assessed patient's morbidity in the first two week and second two weeks with the stent in situ and during the post-stent period using the brief-form Chinese version USSQ, which covers stent-related condition in recent two weeks. (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The pathophysiology of stent-related symptoms may be associated with irritation of the trigone, smooth muscle spasm in ureter and bladder, reflux of urine to kidney, or a combination of them (<xref rid="B18" ref-type="bibr">18</xref>). &#x003b1;1-adrenergic receptors are expressed in ureter, bladder body, bladder neck, urethra and prostate. The benefits of selective &#x003b1;1-blockers are 2-fold: inhibition of &#x003b1;1-adrenergic receptors in bladder neck and prostate to decrease outlet resistance and reflux of urine, and concurrent inhibition of &#x003b1;1-adrenergic receptors in bladder body and ureter to decrease bladder overactivity and ureter spasm, thereby improving both urinary symptoms and pain (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Doxazosin is a long-acting selective &#x003b1;1-adrenergic receptors antagonist with a half life of 16-20 hours. Doxazosin Oral Intake Therapy has been shown to offer enhanced pharmacokinetic profile, delivery rate and tolerability (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). It may also improve lower urinary tract symptoms more completely via additional &#x003b1;-adrenergic receptors in CNS than tamsulosin (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>).</p><p>The beneficial effect of Doxazosin Oral Intake Therapy on stent symptoms was primarily shown in the first two weeks with the stent in situ. The results in the second two weeks with the stent in situ further indicated the efficacy of Doxazosin Oral Intake Therapy on stent symptoms, which were less dependent on patient surgical complications, preoperative condition and postoperative recovery. The outcomes obtained at 4 weeks after stent withdrawal were proposed to be the baseline data without the impact of ureteral calculi and related hydronephrosis (<xref rid="B6" ref-type="bibr">6</xref>). However, we still noted a trend for higher abdominal pain in the placebo group after stent removal; this finding might demonstrate the residual effects of the treatment or the prevalence of symptoms in background population (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Our study has several limitations. Firstly, we didn't evaluate all aspects of stent-related morbidity using USSQ initiated by Joshi et al., because the whole USSQ was not translated, adapted and validated in Chinese population. Secondly, Doxazosin Oral Intake Therapy was not compared with other &#x003b1;-blockers such as alfuzosin and tamsulosin. Thirdly, though the sample size per group was big enough for daytime frequency and flank pain, it might be relatively small to detect small differences of other parameters between two cohorts. Finally, since the brief-form Chinese version USSQ is used to assess symptoms associated with ureteral stent in previous 2 weeks, the discomforts were not evaluated on postoperative day 3 or 1 week after surgery when the outcomes were thought to be more relevant (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Future randomized study with larger patient population using validated USSQ is warranted to further ascertain the efficacy of Doxazosin Oral Intake Therapy on stent-related morbidity and find the best way to address those discomforts by comparison between Doxazosin Oral Intake Therapy and other drugs already studied, such as tamsulosin or anticholinergics.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The administration of Doxazosin Oral Intake Therapy 4mg once daily reduced stent-related urinary symptoms, pain and the negative impact on QoL.</p></sec></body><back><glossary><def-list><def-head>ABBREVIATIONS USED</def-head><def-item><term id="G1">USSQ</term><def><p>= Ureteric Stent Symptom Questionnaire</p></def></def-item><def-item><term id="G2">QoL</term><def><p>= Quality of Life</p></def></def-item><def-item><term id="G3">TEAE</term><def><p>= Treatment Emergent Adverse Event</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimskind</surname><given-names>PD</given-names></name><name><surname>Fetter</surname><given-names>TR</given-names></name><name><surname>Wilkerson</surname><given-names>JL</given-names></name></person-group><article-title>Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically</article-title><source>J Urol</source><year>1967</year><volume>97</volume><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">6025928</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>HB</given-names></name><name><surname>Okeke</surname><given-names>A</given-names></name><name><surname>Newns</surname><given-names>N</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name><name><surname>Timoney</surname><given-names>AG</given-names></name></person-group><article-title>Characterization of urinary symptoms in patients with ureteral stents</article-title><source>Urology</source><year>2002</year><volume>59</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">11927301</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>HB</given-names></name><name><surname>Stainthorpe</surname><given-names>A</given-names></name><name><surname>MacDonagh</surname><given-names>RP</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name><name><surname>Timoney</surname><given-names>AG</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name></person-group><article-title>Indwelling ureteral stents: evaluation of symptoms, quality of life and utility</article-title><source>J Urol</source><year>2003</year><volume>169</volume><fpage>1065</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">12576847</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deliveliotis</surname><given-names>C</given-names></name><name><surname>Chrisofos</surname><given-names>M</given-names></name><name><surname>Gougousis</surname><given-names>E</given-names></name><name><surname>Papatsoris</surname><given-names>A</given-names></name><name><surname>Dellis</surname><given-names>A</given-names></name><name><surname>Varkarakis</surname><given-names>IM</given-names></name></person-group><article-title>Is there a role for alpha1blockers in treating double-J stent-related symptoms?</article-title><source>Urology</source><year>2006</year><volume>67</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">16413328</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beddingfield</surname><given-names>R</given-names></name><name><surname>Pedro</surname><given-names>RN</given-names></name><name><surname>Hinck</surname><given-names>B</given-names></name><name><surname>Kreidberg</surname><given-names>C</given-names></name><name><surname>Feia</surname><given-names>K</given-names></name><name><surname>Monga</surname><given-names>M</given-names></name></person-group><article-title>Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study</article-title><source>J Urol</source><year>2009</year><volume>181</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">19013590</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname><given-names>R</given-names></name><name><surname>Autorino</surname><given-names>R</given-names></name><name><surname>De Sio</surname><given-names>M</given-names></name><name><surname>Giacobbe</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>IM</given-names></name><name><surname>D'Armiento</surname><given-names>M</given-names></name></person-group><article-title>Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study</article-title><source>J Endourol</source><year>2008</year><volume>22</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">18338955</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellis</surname><given-names>AE</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name><name><surname>Manolas</surname><given-names>V</given-names></name><name><surname>Skolarikos</surname><given-names>AA</given-names></name></person-group><article-title>Role of &#x003b1;-blockers in the treatment of stent-related symptoms: a prospective randomized control study</article-title><source>Urology</source><year>2014</year><volume>83</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24210570</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>RS</given-names></name><name><surname>Quinn</surname><given-names>S</given-names></name><name><surname>Mallen</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>D</given-names></name></person-group><article-title>Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis</article-title><source>Int J Clin Pract</source><year>2004</year><volume>58</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14994963</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>JM</given-names></name><name><surname>Desgrandchamps</surname><given-names>F</given-names></name></person-group><article-title>The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia</article-title><source>BJU Int</source><year>2005</year><volume>95</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">15705083</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>KE</given-names></name><name><surname>Lepor</surname><given-names>H</given-names></name><name><surname>Steers</surname><given-names>WD</given-names></name></person-group><article-title>alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms</article-title><source>Prostate Cancer Prostatic Dis</source><year>2000</year><volume>3</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12497103</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>KH</given-names></name><name><surname>Yang</surname><given-names>HJ</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>TK</given-names></name></person-group><article-title>Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy</article-title><source>Urolithiasis</source><year>2013</year><volume>41</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">23515684</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>HB</given-names></name><name><surname>Newns</surname><given-names>N</given-names></name><name><surname>Stainthorpe</surname><given-names>A</given-names></name><name><surname>MacDonagh</surname><given-names>RP</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name><name><surname>Timoney</surname><given-names>AG</given-names></name></person-group><article-title>Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure</article-title><source>J Urol</source><year>2003</year><volume>169</volume><fpage>1060</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">12576846</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Huang</surname><given-names>SW</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group><article-title>Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study</article-title><source>Urol Int</source><year>2009</year><volume>83</volume><fpage>66</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">19641362</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krambeck</surname><given-names>AE</given-names></name><name><surname>Walsh</surname><given-names>RS</given-names></name><name><surname>Denstedt</surname><given-names>JD</given-names></name><name><surname>Preminger</surname><given-names>GM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>JC</given-names></name><etal/></person-group><article-title>A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent</article-title><source>J Urol</source><year>2010</year><volume>183</volume><fpage>1037</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">20092835</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Melotti</surname><given-names>R</given-names></name><name><surname>Timoney</surname><given-names>AG</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name></person-group><article-title>New ureteral stent design does not improve patient quality of life: a randomized, controlled trial</article-title><source>J Urol</source><year>2011</year><volume>185</volume><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">21074809</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>AD</given-names></name><name><surname>Vowler</surname><given-names>SL</given-names></name><name><surname>Johnston</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>N</given-names></name><name><surname>Wiseman</surname><given-names>OJ</given-names></name></person-group><article-title>Meta-analysis showing the beneficial effect of &#x003b1;-blockers on ureteric stent discomfort</article-title><source>BJU Int</source><year>2011</year><volume>108</volume><fpage>1894</fpage><lpage>1902</lpage><pub-id pub-id-type="pmid">21453351</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakoubi</surname><given-names>R</given-names></name><name><surname>Lemdani</surname><given-names>M</given-names></name><name><surname>Monga</surname><given-names>M</given-names></name><name><surname>Villers</surname><given-names>A</given-names></name><name><surname>Koenig</surname><given-names>P</given-names></name></person-group><article-title>Is there a role for &#x003b1;-blockers in ureteral stent related symptoms? A systematic review and meta-analysis</article-title><source>J Urol</source><year>2011</year><volume>186</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">21791359</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellis</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>HB</given-names></name><name><surname>Timoney</surname><given-names>AG</given-names></name><name><surname>Keeley</surname><given-names>FX</given-names><suffix>Jr</suffix></name></person-group><article-title>Relief of stent related symptoms: review of engineering and pharmacological solutions</article-title><source>J Urol</source><year>2010</year><volume>184</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">20723923</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Schwinn</surname><given-names>DA</given-names></name></person-group><article-title>Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">14767264</pub-id></element-citation></ref></ref-list></back></article>